share_log

Insider Sellers Might Regret Selling Peijia Medical Shares at a Lower Price Than Current Market Value

Insider Sellers Might Regret Selling Peijia Medical Shares at a Lower Price Than Current Market Value

內幕賣家可能會後悔以低於當前市值的價格出售培佳醫療股票
Simply Wall St ·  03/23 06:34

Peijia Medical Limited's (HKG:9996) stock price has dropped 15% in the previous week, but insiders who sold CN¥11m in stock over the past year have had less luck. Insiders might have been better off holding onto their shares, given that the average selling price of CN¥10.71 is still below the current share price.

培佳醫療有限公司(HKG: 9996)的股價在前一週下跌了15%,但在過去一年中出售1100萬元人民幣股票的內部人士運氣不佳。鑑於10.71元人民幣的平均售價仍低於當前的股價,內部人士持有股票可能會更好。

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

儘管我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但我們認爲完全忽視內幕交易是愚蠢的。

Peijia Medical Insider Transactions Over The Last Year

培佳醫療去年內幕交易

Over the last year, we can see that the biggest insider sale was by the Executive Director & Company Secretary, Hong Ye, for HK$3.1m worth of shares, at about HK$11.09 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of HK$4.17. So it is hard to draw any strong conclusion from it. Hong Ye was the only individual insider to sell shares in the last twelve months.

在過去的一年中,我們可以看到,最大規模的內幕出售是執行董事兼公司秘書葉宏,出售了價值310萬港元的股票,每股約11.09港元。我們通常不喜歡看到內幕銷售,但是銷售價格越低,我們就越擔心。好消息是,此次大宗交易遠高於當前4.17港元的價格。因此,很難從中得出任何強有力的結論。在過去的十二個月中,葉宏是唯一出售股票的內部人士。

Hong Ye divested 1.04m shares over the last 12 months at an average price of CN¥10.71. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

宏業在過去12個月中以10.71元人民幣的平均價格剝離了104萬股股票。您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!

insider-trading-volume
SEHK:9996 Insider Trading Volume March 22nd 2024
SEHK: 9996 內幕交易量 2024 年 3 月 22 日

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Insider Ownership Of Peijia Medical

培佳醫療的內部所有權

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 3.1% of Peijia Medical shares, worth about HK$86m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。內部人士擁有培佳醫療3.1%的股份,價值約8600萬港元。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。

So What Do The Peijia Medical Insider Transactions Indicate?

那麼,培佳醫療內幕交易表明了什麼?

There haven't been any insider transactions in the last three months -- that doesn't mean much. Still, the insider transactions at Peijia Medical in the last 12 months are not very heartening. But it's good to see that insiders own shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Peijia Medical. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Peijia Medical.

在過去的三個月中,沒有任何內幕交易——這並不意味着什麼。儘管如此,培佳醫療在過去12個月中的內幕交易並不十分令人鼓舞。但很高興看到內部人士擁有該公司的股份。除了了解正在進行的內幕交易外,識別培佳醫療面臨的風險也是有益的。爲了幫助解決這個問題,我們發現了一個警告信號,你應該仔細看看,以便更好地了解培佳醫療。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論